Intra-Cellular Therapies (BSP:I2TC34) Accounts Payable & Accrued Expense : R$571 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Intra-Cellular Therapies Accounts Payable & Accrued Expense?

Intra-Cellular Therapies's quarterly accounts payable & accrued expense increased from Sep. 2023 (R$366 Mil) to Dec. 2023 (R$454 Mil) and increased from Dec. 2023 (R$454 Mil) to Mar. 2024 (R$571 Mil).

Intra-Cellular Therapies's annual accounts payable & accrued expense increased from Dec. 2021 (R$145 Mil) to Dec. 2022 (R$292 Mil) and increased from Dec. 2022 (R$292 Mil) to Dec. 2023 (R$454 Mil).

Intra-Cellular Therapies Accounts Payable & Accrued Expense Historical Data

The historical data trend for Intra-Cellular Therapies's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Accounts Payable & Accrued Expense Chart

Intra-Cellular Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

96.72

84.39

145.49

292.03

453.57

Intra-Cellular Therapies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															309.39	324.71	365.76	453.57	571.45

Intra-Cellular Therapies Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Intra-Cellular Therapies (BSP:I2TC34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (BSP:I2TC34) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ITCI:USA ITCI:Mexico 23I:Germany

Address

430 East 29th Street, New York, NY, USA, 10016

Website

https://www.intracellulartherapies.com

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies (BSP:I2TC34) Headlines

No Headlines